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Aims Cardiac hypertrophy is associated with a reduction in the contractile response to beta-adrenergic stimulation, and
with re-expression of foetal genes such as beta-myosin heavy chain (MHC). However, whether these two




To answer this question, we examined the beta-adrenergic response of individual beta-MHC expressing and non-
expressing myocytes from hypertrophic hearts, using a previously generated mouse model (YFP/beta-MHC) in
which a yellow fluorescent protein (YFP) is fused to the native beta-MHC protein allowing easy identification of
beta-MHC expressing cells. Yellow fluorescent protein/beta-MHC mice were submitted to 4 weeks of transverse
aortic constriction (TAC), and the contractile parameters of isolated individual myocytes in response to the beta-
adrenergic agonist isoproterenol were assessed. Our results demonstrate that the decrease in isoproterenol-
induced cell shortening that develops in TAC hearts occurs only in those hypertrophic myocytes that re-express
beta-MHC. Hypertrophic myocytes that do not express beta-MHC have contractility indices indistinguishable
from non-TAC controls.
Conclusion These data show that the reduction of beta-adrenergic response occurs only in subsets, rather than in all myocytes,
and is coincident with re-expression of beta-MHC.
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Introduction
Re-expression of beta-myosin heavy chain (MHC) is a
well-documented molecular marker of pathological cardiac
hypertrophy.1 Normally, the beta-MHC isoform is expressed in a
developmental stage-specific manner in the mouse ventricle.
Beta-MHC expression is high during embryonic and foetal stages,
but decreases rapidly soon after birth when it is replaced by the
expression of alpha isoform.2 Beta-MHC is re-expressed in the
murine ventricle following cardiac hypertrophy and during
cardiac failure.1 –5 Reversal of cardiac failure is associated with
beta-MHC expression returning to baseline levels.3,6 The
beta-MHC isoform has a lower ATPase activity, but greater force
of contraction than the alpha isoform.7 Recent reports have
demonstrated that even modest increases in the levels of
beta-MHC are accompanied by a significant detriment in
pump function of the heart including a decrease in contractility
(þdp/dt).8,9
At the cellular level, a functional hallmark of cardiac hypertrophy
and heart failure is a depressed contractile response of individual
cardiac myocytes to beta-adrenergic stimulation.10,11 In myocytes
from a healthy adult heart, beta-adrenergic agonists such as
* Corresponding author. Tel: þ1 919 966 6912, Fax: þ1 919 966 8800, Email: jenny_langenbach@med.unc.edu
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
European Journal of Heart Failure (2009) 11, 648–652
doi:10.1093/eurjhf/hfp073
isoproterenol induce a short-term hypercontractile response by
increasing the degree of cell shortening and by increasing the vel-
ocities of contraction and relaxation. However, myocytes sampled
from the hearts of mice undergoing hypertrophy and heart failure
show a markedly decreased response to beta-adrenergic stimu-
lation, manifested as a smaller increase in cell shortening and in
the velocities of contraction and relaxation.12,13 This effect is a
direct consequence of a decrease in the number of beta-adrenergic
receptors as well as impaired function of the receptor.14–18 The
decrease in beta-adrenergic response is directly correlated with
the severity of the cardiac phenotype, and genetic and therapeutic
interventions that maintain normal beta-adrenergic receptor
numbers and signalling have a substantial positive impact on
heart function.10,12,19 –23
At the level of individual myocytes, the relationship between the
re-expression of beta-MHC and reduced beta-adrenergic respon-
siveness is, however, not known. Thus, it is not known whether
these two markers of cardiac pathology always develop together
in all the cells that change or arise independently in different
responding cells. To answer this question, we evaluated the con-
tractile parameters of individual beta-MHC expressing and non-
expressing cardiac myocytes isolated from the same heart
exposed to a hypertrophic stimulus.
Methods
The generation of YFP/beta-MHC animals, and procedures for mor-
phometrical analyses, confocal image acquisition, transverse aortic
constriction (TAC), and myocyte isolation have been described pre-
viously.24,25 The investigation conforms with the Guide for the Care
and Use of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85-23, revised 1985).
Evaluation of myocyte function
Myocytes were placed in a 0.5 mL chamber with 1.8 mM Ca2þ
Tyrode’s solution at room temperature, and visualized with a Nikon
inverted microscope with a solid-state CCD camera attached and dis-
played on a video monitor. The expression of YFP in individual cells
was scored using an epifluorescence apparatus attached to the micro-
scope. Two platinum electrodes connected to a stimulator were used
to field stimulate the myocytes with pulse duration of 5 ms and a fre-
quency of 0.5 Hz. Myocyte cell edges are enhanced and processed with
a video edge motion detection system (Crescent Electronics) at a
sampling rate of 240 Hz. Recordings were performed either under
basal conditions or after isoproterenol stimulation (1 mm). Calibrated
myocyte lengths were converted from analog to digital on-line
(MacLab) and stored on computer. All myocytes were studied
within 1–2 h after myocyte isolation. Data from three consecutive
contractions were averaged. Approximately 15 myocytes from each
category were studied. The recordings for the control group were
acquired from untreated hearts which contain only non-yellow
myocytes. Those for the TAC group were acquired from yellow and
non-yellow myocytes isolated from single hearts. The data for basal
and isoproterenol stimulation within each of the three groups
(control non-yellow, TAC non-yellow, TAC yellow) were acquired
from different cells and analysed with ANOVA with Newman–Keuls
correction using Graphpad Prizm software. Student’s t-test was used
for morphometrical analyses (Figure 1).
Results
To determine the association between the state of beta-MHC
expression and the contractile parameters of individual cells, we
used mice that express a yellow fluorescent protein (YFP) fused
to the amino terminal of the beta-MHC (YFP/beta-MHC) as
described previously.24 This YFP/beta-MHC allele is appropriately
regulated during development, and accurately tracks the
expression of the wild-type beta-MHC allele in response to
cardiac hypertrophy in vivo. In our present experiments, cardiac
Figure 1 (A) Morphometrical analyses. Cross-sectional areas
(sq. microns) of myocytes from animals that were untreated
(UT) or that underwent TAC for 4 weeks (TAC) grouped
according to their yellow fluorescence (yellow cells, Y or non-
yellow cells, NY). A total of 300 cells (100 cells/heart) from
three hearts/condition were analysed. Error bars denote SE.
(B) Yellow fluorescent images (YFP) and Cy5 fluorescence for
WGA lectin (pseudo-coloured blue) acquired from the left ven-
tricular free walls of control (UT) or TAC-treated (TAC) hearts
with 20x oil objective. (C) Yellow fluorescent confocal images of
ventricular sections from untreated (UT) or TAC-treated (TAC).
Overlapping images were acquired using a 4 objective and
stitched together using ImageJ. ***P , 0.0001.
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hypertrophy was induced in 4-month-old heterozygous YFP/
beta-MHC animals by 4 weeks of TAC. Echocardiography was
conducted on these animals and the data (Table I) show that the
TAC-treated animals were in a state of heat failure (%FS 29 vs.
43 for control, P , 0.01), but without overt LV dilation (no signifi-
cant differences in the levels of end-systolic and end-diastolic LV
diameters). Morphometric analyses (Figure 1) of myocytes from
the left ventricular free walls of untreated and TAC-treated
hearts show that in the TAC hearts the cross-sectional areas of
myocytes are larger than myocytes from untreated hearts regard-
less of whether the TAC myocytes express YFP/beta-MHC or not.
Furthermore, the cross-sectional areas of the TAC myocytes that
express YFP/beta-MHC (column 3) are not significantly different
(P ¼ 0.6) from TAC myocytes from the same hearts that do not
express YFP/beta-MHC (column 2), demonstrating that the YFP/
beta-MHC expressing cells are as hypertrophic as the non-YFP/
beta-MHC expressing cells. This confirms previous observations
by ourselves24 and by others9 that cellular hypertrophy is not obli-
gatorily coupled to the re-expression of YFP/beta-MHC. Ventricu-
lar sections from a TAC or control heart were analysed for YFP
fluorescence using confocal microscopy, and Figure 1C illustrates
the spatial distribution of YFP expressing cells in the control
(UT) or TAC-treated heart.
To test whether the YFP/beta-MHC expressing and non-
expressing myocytes from TAC hearts have different contractile
responses to beta-adrenergic stimulation, myocytes from
untreated control, and TAC-treated hearts were isolated by col-
lagenase treatment. The contractile parameters were then
assessed during basal (unstimulated) conditions or after stimulation
with the beta-adrenergic agonist isoproterenol (1 mm). Under
basal conditions, the percent cell shortening (%CS, Figure 2A), as
well as the rates of relaxation (dl/dt, Figure 2B) and shortening
(2dl/dt, Figure 2C) of YFP/beta-MHC expressing cells from TAC
hearts are not significantly different from YFP/beta-MHC non-
expressing TAC myocytes from the same hearts (P . 0.05), or
from control hearts (P . 0.05). Isoproterenol stimulation of myo-
cytes from control hearts induces a marked increase in the %CS
(Figure 2A); as well as in the velocities of relaxation (Figure 2B)
and shortening (Figure 2C). Isoproterenol stimulation of YFP/
beta-MHC non-expressing cells from the TAC hearts likewise
induced a marked and significant increase in the %CS, and vel-
ocities of relaxation and shortening (Figure 2A–C ), and these
increases are virtually identical to those of control cells
(Figure 2A–C ). In marked contrast, isoproterenol stimulation of
YFP/beta-MHC expressing cells from the TAC hearts changed
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Table 1 Echocardiographic parameters
Untreated TAC
n 9 10
LVEDD (mm) 3.1+0.2 3.3+0.2
LVESD (mm) 1.8+0.2 2.3+0.2
% FS 43+3 29+3*
IVSD th (mm) 1.1+0.1 1.2+0.1
IVSS th (mm) 1.7+0.1 1.7+0.1
PWD th (mm) 1.2+0.1 1.2+0.1
PWS th (mm) 1.8+0.1 1.5+0.1
HR (b.p.m.) 604+57 506+54
Animals were untreated or TAC treated for 4 weeks.
n, number of animals in each group; LVEDD, left ventricular end-diastolic diameter;
LVESD, left ventricular end-systolic diameter; IVSD th, inter ventricular septum
thickness diastole; FS, fractional shortening; IVSS th, inter-ventricular septum
thickness systole; PWD th, posterior wall thickness diastole; PWS th, posterior
wall thickness systole; HR, heart rate.
*P , 0.01.
Figure 2 Cell-shortening parameters of myocytes. Fractional
cell shortening (% cell shortening, Y-axis) (A), rate of cell relaxation
(dl/dt, B), and rate of cell shortening (2dl/dt, C) of myocytes from
YFP/beta-MHC animals that were either untreated (columns
marked ‘UT’), or treated with TAC for 4 weeks (columns
marked ‘TAC’) that either did not express YFP-beta-MHC (open
bars,) or that did express YFP-beta-MHC (yellow bars). Myocytes
from each group were either unstimulated (2) or stimulated with
1 mM isoproterenol (þ). Each experimental group consists of
approximately 15 myocytes/heart, and five hearts/condition.
Error bars denote SE. *P , 0.05, **P , 0.01, ***P , 0.001,
ANOVA with Newman–Keuls correction.
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the %CS minimally after stimulation (Figure 2A, P . 0.05); the %CS
in the YFP/beta-MHC expressing TAC myocytes is significantly
lower than that in either the YFP/beta-MHC non-expressing
TAC myocytes (P , 0.05) or the control myocytes (Figure 2A,
P , 0.01). The changes in rates of relaxation and shortening, of
the YFP/beta-MHC expressing TAC myocytes (Figure 2B and C ),
in response to isoproterenol stimulation, are also significantly
lower than those of the YFP/beta-MHC non-expressing TAC myo-
cytes from the same hearts (Figure 2B and C, P , 0.01), or from
cells of the control heart (Figure 2B and C, P , 0.01). These
results demonstrate that those cardiac myocytes that re-express
YFP/beta-MHC are also those in which the beta-adrenergic
response is decreased.
To exclude the possibility that the changes in isoproterenol-
induced contractility observed in the YFP/beta-MHC expressing
myocytes might be due to the toxic effects of the fluorescent
protein expression, we tested the contractile parameters of myo-
cytes from an untreated transgenic animal that expresses GFP
under the control of the cardiac alpha MHC promoter at a high
level. The data (not shown) show that GFP-expressing myocytes
from an untreated transgenic mouse display the same contractile
parameters during basal conditions and in response to isoprotere-
nol stimulation as the myocytes from the untreated non-transgenic
hearts.
Taken together, our results demonstrate that the decrease in
beta-adrenergic responsiveness in individual myocytes isolated
from TAC treated hearts is co-incident with YFP/beta-MHC
expression. Myocytes that do not express YFP/beta-MHC isolated
from the same TAC treated hearts have a normal beta-adrenergic
response, even though the YFP/beta-MHC non-expressing cells are
as hypertrophic as those that express YFP/beta-MHC.
Discussion
We have previously demonstrated that, during cardiac hypertro-
phy, beta-MHC re-expression occurs in subsets (approximately.
38%) rather than in all hypertrophic myocytes, indicating that the
pathways that induce cellular hypertrophy are not obligatorily
coupled to the pathways that induce beta-MHC.24,26 These
YFP-expressing myocytes are mostly found in the left ventricle,
generally in the mid-ventricular wall, and surround areas of fibrosis.
In our current report, we demonstrate that decreased contractile
response to beta-adrenergic stimulation also occurs in subsets of
myocytes and is co-incident with beta-MHC re-expression;
beta-MHC non-expressing cells from the same TAC hearts show
a normal contractile response to beta-adrenergic stimulation
even though they are equally hypertrophic.
Although we have demonstrated that the reduction of
beta-adrenergic response is coincident with beta-MHC re-expression
in individual cells in vivo, our data do not show whether the reduction
of beta-adrenergic response and beta-MHC re-expression are linked
in a cause-and-effect relationship or are the coincidental outcomes of
some other change. However, genetic means of rescuing pathological
heart failure by decreasing beta-adrenergic stimulation decrease
beta-MHC expression.3,6 Similarly, beta-blocker therapy of hearts in
failure shows a decrease in the levels of beta-MHC mRNA along
with the improvement of cardiac function.27,28 Furthermore, in
neonatal rat myocytes, isoproterenol induces both a decrease in
beta-adrenergic responsiveness, and an increase in beta-MHC
expression.29 These observations indicate that agents which increase
or decrease beta-adrenergic responsiveness also lead to changes in
beta-MHC regulation, and that pathogenic stimulation that promote
beta-adrenergic receptor downregulation/desensitization will also
cause beta-MHC re-expression. Future studies addressing whether
the beta-MHC expressing myocytes also show an altered response
to other agonists would be instrumental in dissecting the pathways
that link beta-MHC re-expression to other pathological stimuli.
The reduction of beta-adrenergic response in myocytes during
TAC and heart failure has been well documented.10–13,30,31 Our
present results demonstrate that the reduction in beta-adrenergic
response in myocytes following hypertrophy induced by TAC
occurs in subsets rather than in all myocytes. It has been proposed
that the decrease in beta-adrenergic responsiveness of cardiac
myocytes during heart failure may be a consequence of increase
in circulating catecholamines.32 However, different regions of the
same heart have different levels of catecholamines, and myocytes
from the right ventricle of animals with increased circulating cat-
echolamines do not show signs of decreased beta-adrenergic
response.33 These results and our current finding that only
subsets of myocytes within the heart display decreased
beta-adrenergic responsiveness support a hypothesis that local,
rather than systemic, increases in catecholamine levels cause the
reduction in beta-adrenergic responsiveness and increase in
beta-MHC expression that we observe in individual myocytes.
Some comment is required on the apparent discrepancy
between our results that show normal basal contractile behaviour
in beta-MHC expressing cells and the results of Tardiff et al.9 that
showed a decrease in baseline contractile parameters in beta-MHC
expressing cells. Important differences exist between the two
studies. The Tardiff study used a mouse model in which
beta-MHC was transgenically over-expressed in all cardiac myo-
cytes (12% of total MHC). In contrast, in our studies, beta-MHC
was re-expressed in response to pressure overload and occurred
in subsets of cells. Furthermore, while the Tardiff study conducted
contractility studies (measuring dp/dt) on the whole heart using
retrograde perfusion on a Langendorff apparatus, our contractility
studies (measuring cell shortening) were carried out at the level of
individual isolated cardiac myocytes.
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